

Blue Star (India) (BLSTR)

Consumer Durables | 4QFY24 Result Update

ACCUMULATE

CMP: Rs1,448 | Target Price (TP): Rs1,435 | Downside: 1%

May 03, 2024

Continues to positively surprise us

Key Points

- Both topline and EBITDA margin were above our estimates by 8% and 41bps respectively, due to higher-than-anticipated growth in RAC.
- Blue Star improved its RAC market share by 25bps in FY24 to 13.75%, with RAC volume at 1mn+ units. While there was no price hike in 4QFY24 and YTD 1QFY25 (and no massive price disruption as well), strong volume growth is expected in 1QFY25 too, on the back of strong summers.
- While total order booking de-grew by ~2% YoY in FY24, upward traction in manufacturing and data centre + pick up in infra cycle are expected to pump up order book growth in FY25. Currently, the company is focused on expediting the speed of execution of its order book & collection of dues.
- We draw high comfort in its business model due to its strategy of chasing profitability and FCF, presence in high growth Comm. Refrigeration and high quality order booking from EMPS. **While we remain structurally positive on long term prospects, the stock has had a good price run-up in recent months (~55%+ YTD CY24). As a result, we believe that the share is currently fairly priced, and therefore, maintain ACCUMULATE with SOTP-based TP of Rs1,435 (42x blended PE on FY26E EPS). Nonetheless, we believe it is a long term compounder, and therefore, it should be accumulated at every dip.**

4QFY24 performance update: Topline growth of 26.8% YoY was due to strong performance across segments – UCP (up 34.8% YoY – led by volume growth on the back of affordable products introduced + 80-months comprehensive warranty issued), and EMPS (up 20.3% YoY). While gross margin expanded by 42bps YoY, it compressed by similar bps QoQ due to the rise in raw material prices. EBITDA margin expanded by 44bps YoY on account of favourable product mix.

1QFY25 expected to be a strong quarter for RAC: As per management, primary sales for RAC in March'24 grew by 40% YoY on volume basis. April'24 clocked in stronger growth at ~65-75% volume-wise, while secondary & tertiary sales grew by 70-90% volume-wise in the same period. April was the peak month in terms of best sales, and May is expected to deliver lower growth due to enough inventory being pushed in the channel in April + most growth being frontloaded in April itself. The RAC industry is expected to clock in ~25%+ value growth in 1QFY25. We expect Blue Star to beat industry growth by ~350-400bps.

Trial orders in process for CAC – a positive: Blue Star is in the phase of developing, testing and getting approval for Europe & North American markets. The trial orders are being executed currently, and we expect some export revenue booking in 2HFY25. We believe this could be the alpha generator as export market in CAC has better opportunities compared to RAC and Blue Star will be able to leverage its domestic expertise for international markets too.

Others: Management's focus in FY25 would be to maintain and improve UCP margins – by not getting into price discounting, thus, ensuring prudent cash flow management. Its focus will also be on effecting talent management.

Est Change	No change
TP Change	Upward
Rating Change	No change

Company Data and Valuation Summary

Reuters:	BLUS.BO
Bloomberg:	BLSTR IN Equity
Mkt Cap (Rsbn/US\$bn):	297.7 / 3.6
52 Wk H / L (Rs):	1,514 / 693
ADTV-3M (mn) (Rs/US\$):	510.0 / 6.1
Stock performance (%) 1M/6M/1yr:	7.4 / 49.0 / 101.3
Nifty50 performance (%) 1M/6M/1yr:	1.6 / 3.6 / 23.1

Shareholding	2QFY24	3QFY24	4QFY24
Promoters	36.5	36.5	36.5
DII's	25.2	24.8	24.7
FII's	14.9	15.4	15.9
Others	23.4	23.3	22.9
Pro pledge	0.0	0.0	0.0

Financial and Valuation Summary

Particulars (Rs Mn)	FY23	FY24	FY25E	FY26E
Net Sales	79,773	96,854	1,19,235	1,42,898
Growth YoY (%)	31.6	21.4	23.1	19.8
Gross Margin (%)	22.5	23.7	24.5	25.0
EBITDA	4,928	6,649	8,590	10,649
EBITDA Margin (%)	6.2	6.9	7.2	7.5
Adj. PAT	2,862	4,150	5,520	6,965
Adj. PAT Margin (%)	3.6	4.3	4.6	4.9
Adj. PAT YoY Growth (%)	70.7	45.0	33.0	26.2
Adj. EPS(Rs)	13.9	20.2	26.8	33.9
ROCE (%)	23.9	24.2	25.4	28.4
ROCE (Post-Tax) (%)	17.3	18.0	19.0	21.3
ROE (%)	34.1	21.1	20.8	24.1
P/E	104.0	71.7	53.9	42.7
EV/EBITDA	61.1	44.5	34.6	27.7
P/B	22.4	11.4	11.1	9.7

Source: Bloomberg, Company, Nirmal Bang Institutional Equities Research

Key Links–

[4QFY24Results](#); [4QFY24PressRelease](#)

Please refer to the disclaimer towards the end of the document.

Exhibit 1: 4QFY24 Consolidated Performance

Particulars (Rsmn)	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24	4Q24	FY23	FY24
Net Sales	19,770	15,823	17,942	26,238	22,260	18,904	22,412	33,278	79,773	96,854
YoY Change (%)	87.9	27.6	19.1	16.4	12.6	19.5	24.9	26.8	31.6	21.4
Gross Profit	4,156	3,667	4,021	6,112	4,938	4,686	5,417	7,892	17,957	22,934
Margin (%)	21.0	23.2	22.4	23.3	22.2	24.8	24.2	23.7	22.5	23.7
EBITDA	1,233	856	1,047	1,792	1,450	1,227	1,554	2,419	4,928	6,649
YoY Change (%)	192.0	21.1	15.6	25.3	17.6	43.3	48.4	35.0	42.2	34.9
Margin (%)	6.2	5.4	5.8	6.8	6.5	6.5	6.9	7.3	6.2	6.9
Depreciation	220	245	156	227	228	230	235	283	848	976
Interest	106	121	139	181	180	177	102	122	547	581
Other Income	105	86	52	67	94	130	127	124	309	474
Extraordinary Items	-	-	-	1,708	-	-	-	-	1,708	-
PBT (bei)	1,012	576	804	1,450	1,136	950	1,343	2,138	3,842	5,567
PBT	1,012	576	804	3,158	1,136	950	1,343	2,138	5,550	5,567
Tax	263	149	216	918	302	243	339	544	1,547	1,429
ETR(%)	26.0	25.9	26.9	29.1	26.6	25.5	25.3	25.5	27.9	25.7
Reported PAT	742	426	584	2,241	834	706	1,007	1,587	4,096	4,137
Adj. PAT	742	426	584	849	834	706	1,007	1,587	2,862	4,137
YoY Change (%)	485.1	34.9	22.6	11.3	12.3	66.0	72.4	86.9	70.4	44.5
Adj. EPS	3.9	2.2	3.0	4.4	4.3	3.4	4.9	7.7	13.9	20.1

Source: Company, NirmalBang Institutional Equities Research

Exhibit 2: 4QFY24 Segmental Performance

Particulars (Rsmn)	4Q23	3Q24	4Q24	YoY(%)	QoQ(%)	FY23	FY24	YoY(%)
Net Sales								
EPAC	12,526	11,823	15,068	20.3	27.4	40,114	47,155	17.6
Unitary Products	12,677	9,554	17,089	34.8	78.9	36,251	45,922	26.7
PE&IS	1,035	1,035	1,121	8.3	8.3	3,348	3,777	12.8
Sales Mix (%)								
EPAC	47.7	52.8	45.3			50.3	48.7	
Unitary Products	48.3	42.6	51.4			45.5	47.4	
PE&IS	3.9	4.6	3.4			4.2	3.9	
EBIT								
EPAC	992	967	1,125	13.4	16.4	2,768	3,411	23.2
Unitary Products	1,070	679	1,414	32.2	108.2	2,823	3,603	27.6
PE&IS	198	152	136	(31.6)	(10.8)	505	515	2.0
EBIT Margin (%)								
EPAC	7.9	8.2	7.5	(45) bps	(71) bps	6.9	7.2	33 bps
Unitary Products	8.4	7.1	8.3	(16) bps	117 bps	7.8	7.8	6 bps
PE&IS	19.2	14.7	12.1	(705) bps	(258) bps	15.1	13.6	(145) bps

Source: Company, NirmalBang Institutional Equities Research

Exhibit 3: Actual Performance vs NBIE & Consensus Estimates

4QFY24 (RsMn)	Actuals	Our Estimate	Deviation (%)	BBG Estimates	Deviation (%)
Net Sales	33,278	30,566	8.9	31,125	6.9
EBITDA	2,419	2,098	15.3	2,161	11.9
EBITDA Margin (%)	7.3	6.9	41 bps	6.9	33 bps
Adj. PAT	1,587	1,322	20.1	1,535	3.4

Source: Company, NirmalBang Institutional Equities Research

Exhibit 4: Change in Our Estimates


Description (Rsmn)	FY25E			FY26E		
	Old	New	Change (%)	Old	New	Change (%)
Net Sales	1,14,669	1,19,235	4.0	1,36,576	1,42,898	4.6
EBITDA	8,776	8,590	(2.1)	10,891	10,649	(2.2)
EBITDA Margin (%)	7.7	7.2	(45) bps	8.0	7.5	(52) bps
Adj. PAT	5,557	5,520	(0.7)	7,137	6,965	(2.4)
Adj. EPS	27.0	26.8	(0.6)	34.7	33.9	(2.4)

Source: Company, NirmalBang Institutional Equities Research


Key Concall Highlights:

- At the end of 4QFY24, EMPS carry forward order book grew by 13.5% YoY to Rs54.66bn. Overall order book grew by 12.3% YoY to Rs56.97bn in FY24 from Rs50.73bn in FY23
- In the EMP business, order inflow stood at Rs12.27bn in 4QFY24 vs Rs13.30bn in 4QFY23, a decline of 7.8% YoY due to a slowdown in the commercial building construction sector and the union elections
- In EMPS business, while the commercial buildings segment continued to witness a slowdown and delay in order finalizations, orders from manufacturing & data centres remained healthy
- CAC continued to witness strong traction from OEMs, hospitals, offices, and educational institutions
- Blue Star continued to maintain a good position in Centrifugal Chillers, Screw Chillers and the VRF segment
- The management is looking at an 18-month timeline to ramp up its export business. Currently, it is executing trial orders in these markets. Meanwhile, the US market is expected to pick up post-elections; it is leveraging this slowdown to focus on product development. The company is also highlighting that it is not selling regular CAC, but rather decarbonization and energy efficiency products which require obtaining necessary approvals, navigating regulatory requirements, and building brand share
- Blue Star continues to maintain leadership position in deep freezers, modular cold room and storage water coolers
- The non-destructive testing business continued to gain traction due to the expansion of capacity related to the 'Make in India' initiative and the implementation of high-quality standards across industries. The Healthcare business is also benefiting due to the expansion of semi-rural healthcare infrastructure in the country and increased investments in the sector
- Capital employed increased to Rs21.6bn at the end of FY24 vs Rs15.4bn at the end of FY23, primarily owing to capital investments
- The company aims to gain market share in the affordable segment, particularly targeting Tier 3, 4, and 5 markets, where a significant portion of demand originates
- The diversification of product range, specifically with the introduction of affordable RAC, was the tailwind in surpassing the milestone of selling 1 million units.
- Primary sales of RAC in March 24 increased by 40% year-on-year in volume. The growth continued into April 2024, with primary sales showing even stronger growth ranging from ~65% to 75%. Furthermore, secondary and tertiary sales also saw substantial volume-wise growth of ~70% to 90% during the same period
- The RAC and Commercial Refrigeration divisions enjoy similar levels of profitability


- Demand has remained strong in 1QFY25 and there have been no price increases between 4QFY24 and 1QFY25. There have also been no significant price disruptions in the market.
- Blue Star Ltd. is focussed on expanding its distribution network and enhancing its R&D and manufacturing capabilities to boost brand recognition. The company is recognized by the Government of India for its adoption of eco-friendly technologies, contributing to sustainable growth.

Exhibit 5: Revenue Trend



Source: Bloomberg, Nirmal Bang Institutional Equities Research

Exhibit 6: Margin Trend


Source: Bloomberg, Nirmal Bang Institutional Equities Research

Exhibit 7: UCP Segment Trend



Source: Bloomberg, Nirmal Bang Institutional Equities Research

Exhibit 8: EMPS Segment Trend


Source: Bloomberg, Nirmal Bang Institutional Equities Research

Exhibit 9: One-Year Rolling Forward P/E Chart


Source: Bloomberg, Nirmal Bang Institutional Equities Research



Source: Bloomberg, Nirmal Bang Institutional Equities Research

Financials

Exhibit 10: Income Statement

Y/E March (Rs Mn)	FY22	FY23	FY24	FY25E	FY26E
Net Sales	60,641	79,773	96,854	1,19,235	1,42,898
% Growth	42.2	31.6	21.4	23.1	19.8
Rm Costs	47,332	61,817	73,920	90,022	1,07,173
Gross Profit	13,309	17,957	22,934	29,213	35,724
Gross Margin (%)	21.9	22.5	23.7	24.5	25.0
Staff Cost	5,086	5,922	7,495	9,539	11,432
Other Expenses	4,759	7,107	8,790	11,083	13,644
EBITDA	3,465	4,928	6,649	8,590	10,649
% Growth	44.5	42.2	34.9	29.2	24.0
EBITDA Margin (%)	5.7	6.2	6.9	7.2	7.5
Other Income	357	309	474	350	350
Interest	464	547	581	425	400
Depreciation	860	848	976	1,143	1,295
Exceptional Items	0	1,708	0	0	0
Profit Before Tax	2,498	5,550	5,567	7,373	9,304
Tax	829	1,547	1,429	1,856	2,342
Reported Net Profit	1,677	4,005	4,150	5,520	6,965
Adj. Net Profit	1,677	2,862	4,150	5,520	6,965
Adj. PAT Margin	2.8	3.6	4.3	4.6	4.9
Adj. Eps (Rs)	8.2	13.9	20.2	26.8	33.9

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 11: Balance Sheet

Y/E March (Rs Mn)	FY22	FY23	FY24	FY25E	FY26E
Share Capital	193	193	411	411	411
Reserves	9,983	13,114	25,690	26,507	30,388
Net Worth	10,176	13,307	26,101	26,919	30,799
Minority Interest	30	32	26	26	26
Total Loans	4,778	5,776	1,666	4,000	4,000
Liabilities	14,984	19,115	27,793	30,944	34,825
Net Block	3,911	7,999	10,713	15,573	17,278
CWIP& Intangible Assets	1,940	1,423	2,203	500	500
Investments	1,623	1,481	2,668	2,668	2,668
Inventories	11,442	14,334	14,072	16,843	19,449
Debtors	11,897	15,488	19,526	21,017	23,700
Cash & Bank	2,697	2,433	3,774	4,058	6,851
Other Current Assets	9,340	11,235	13,155	13,506	16,383
Total Current Assets	35,376	43,490	50,526	55,423	66,383
Creditors	20,417	25,112	26,166	30,318	36,468
Other Current Liabilities	7,726	10,246	12,154	12,906	15,540
Total Current Liabilities	28,143	35,358	38,320	43,224	52,008
Net Current Assets	7,234	8,132	12,206	12,200	14,376
Deferred Tax Asset (Net)	276	79	3	3	3
Total Assets	14,984	19,115	27,793	30,944	34,825

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 12: Cash Flow

Y/E March (Rs Mn)	FY22	FY23	FY24	FY25E	FY26E
Ebit	2,605	4,080	5,673	7,448	9,354
(Inc)/Dec In Working Capital	(2,440)	(1,162)	(2,732)	290	617
Cash Flow From Operations	165	2,918	2,941	7,737	9,971
Other Income	357	309	474	350	350
Depreciation	860	2,556	976	1,143	1,295
Tax Paid (-)	(630)	(1,351)	(1,352)	(1,856)	(2,342)
Net Cash From Operations	760	4,433	3,050	7,377	9,277
Capital Expenditure (-)	(2,160)	(4,419)	(4,470)	(4,300)	(3,000)
Net Cash After Capex	(1,399)	14	-1,420	3,077	6,277
Interest Paid (-)	(464)	(547)	(581)	(425)	(400)
Dividends Paid (-)	(963)	(963)	(2,673)	(2,878)	(3,084)
Inc./(Dec.) In Total Borrowings	262	998	(4,110)	2,334	-
(Inc.)/Dec. In Investments	1,326	142	(1,187)	-	-
Cash From Financial Activities	164	(367)	(8,339)	(970)	(3,484)
Others	809	285	11,175	(1,824)	0
Opening Cash	3,322	2,697	2,433	3,774	4,058
Closing Cash	2,697	2,433	3,774	4,058	6,851
Change In Cash	(625)	(264)	1,341	284	2,793

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 13: Key Ratios

Y/E March	FY22	FY23	FY24	FY25E	FY26E
Per Share (Rs)					
Adjusted EPS	8.2	13.9	20.2	26.8	33.9
Book Value	49.5	64.7	126.9	130.9	149.8
Valuation (X)					
P/E	177.5	104.0	71.7	53.9	42.7
P/BV	29.3	22.4	11.4	11.1	9.7
EV/EBITDA	86.5	61.1	44.5	34.6	27.7
EV/Sales	4.9	3.8	3.1	2.5	2.1
Return Ratio (%)					
RoCE	18.4	23.9	24.2	25.4	28.4
RoCE (Post-Tax)	12.3	17.3	18.0	19.0	21.3
RoE	17.6	34.1	21.1	20.8	24.1
RoIC	29.3	31.5	31.0	32.7	37.8
Profitability Ratio (%)					
EBITDA Margin	5.7	6.2	6.9	7.2	7.5
EBIT Margin	4.3	5.1	5.9	6.2	6.5
PAT Margin	2.8	3.6	4.3	4.6	4.9
Turnover Ratio					
Total Asset Turnover Ratio (X)	4.3	4.7	4.1	4.1	4.3
Debtor Days	60	63	66	71	66
Inventory Days	78	76	70	75	72
Creditors Days	141	134	127	135	135
Solvency Ratio (X)					
Net Debt-Equity	0.2	0.3	(0.1)	(0.0)	(0.1)
Debt-Equity	0.5	0.4	0.1	0.1	0.1

Source: Company, Nirmal Bang Institutional Equities Research


Rating Track

Date	Rating	Market price (Rs)	Target price (Rs)
29 March 2019	Buy	335	408
9 April 2019	Buy	343	408
6 May 2019	Buy	349	418
9 July 2019	Buy	367	418
14 August 2019	Buy	354	418
23 September 2019	Buy	398	483
7 October 2019	Buy	403	483
15 November 2019	Buy	406	485
9 January 2020	Buy	413	485
31 January 2020	Buy	416	485
26 March 2020	Buy	258	428
9 April 2020	Buy	252	428
13 May 2020	Buy	235	273
9 July 2020	Buy	245	273
8 August 2020	Buy	249	288
23 September 2020	Accumulate	324	335
9 October 2020	Accumulate	316	335
29 October 2020	Accumulate	314	330
7 January 2021	Accumulate	401	420
31 January 2021	Buy	368	438
9 April 2021	Buy	456	438
10 May 2021	Accumulate	422	425
05 August 2021	Accumulate	429	410
26 September 2021	Accumulate	449	445
30 October 2021	Accumulate	480	475
03 February 2022	Accumulate	498	488
21 February 2022	Accumulate	525	523
08 May 2022	Accumulate	536	600
07 August 2022	Buy	496	600
19 September 2022	Buy	568	670
06 November 2022	Buy	612	705
1 February 2023	Buy	615	708
22 March 2023	Accumulate	724	755
6 May 2023	Accumulate	717	770
05 August 2023	Accumulate	762	745
31 October 2023	Buy	874	1,015
30 December 2023	Buy	945	1,100
31 January 2024	Accumulate	1,099	1,215
03 May 2024	Accumulate	1,448	1,435

Share price has been adjusted for 1:1 Bonus

Coverage was transferred to Natasha Jain with effect from 1st July 2023

Rating Track Graph



DISCLOSURES

This Report is published by Nirmal Bang Equities Private Limited (hereinafter referred to as “NBEPL”) for private circulation. NBEPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH000001436. NBEPL is also a registered Stock Broker with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments.

NBEPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets.

NBEPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBEPL, its associates or analyst or his relatives do not hold any financial interest in the subject company. NBEPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBEPL or its associates or Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report.

NBEPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBEPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company and NBEPL / analyst has not been engaged in market making activity of the subject company.

Analyst Certification: I, Natasha Jain, research analyst, hereby certify that the views expressed in this research report accurately reflects my personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst is principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

Disclaimer

Stock Ratings Absolute Returns

BUY > 15%

ACCUMULATE -5% to 15%

SELL < -5%

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. NBEPL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader.

This research has been prepared for the general use of the clients of NBEPL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NBEPL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBEPL & its group companies to registration or licensing requirements within such jurisdictions.

The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBEPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NBEPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This information is subject to change without any prior notice. NBEPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBEPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.

Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBEPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither NBEPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report.

Copyright of this document vests exclusively with NBEPL.

*"Registration granted by SEBI and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors." Our reports are also available on our website www.nirmalbang.com

Access all our reports on Bloomberg, Thomson Reuters and Factset.

Team Details:			
Name		Email Id	Direct Line
Rahul Arora	CEO	rahul.arora@nirmalbang.com	-
Krishnan Sambamoorthy	Head of Research	krishnan.s@nirmalbang.com	+91 22 6273 8210
Dealing			
Ravi Jagtiani	Dealing Desk	ravi.jagtiani@nirmalbang.com	+91 22 6273 8230, +91 22 6636 8833
Michael Pillai	Dealing Desk	michael.pillai@nirmalbang.com	+91 22 6273 8102/8103, +91 22 6636 8830

Nirmal Bang Equities Pvt. Ltd.

Correspondence Address

B-2, 301/302, Marathon Innova,
 Nr. Peninsula Corporate Park,
 Lower Parel (W), Mumbai-400013.
 Board No. : 91 22 6273 8000/1; Fax. : 022 6273 8010